25 September 2023
25 September 2023
Although pain affects millions of people worldwide, the industry is still struggling in the ongoing search for safe and effective medication.
The biopharma giant's decision to end its partnership with I-Mab follows it ending a trial for the drug early.
The Phase III trial of Luthathera and long-acting octreotide combination as a first-line therapy showed improved progression-free survival in treating GEP-NETs.
The results of Seagen and Astella’s Phase III trial of Padcev and Keytruda will be presented during an upcoming medical meeting.
Datopotamab deruxtecan demonstrated a clinically meaningful improvement in the dual primary endpoint of OS and PFS.
Luminate is an integrin regulator that controls several pathways of oxidative stress response.
The companies plan to expand the use of BSG005 for similar patient groups in the US and EU, after completing trials in India.
The company will complete dosing late this year while a study readout is expected early next year.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
